Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Yoon, Ja K ^a   Kim, Do H ^a   Koo, Ja S ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; Metabolism; Molecular subtype; Sarcosine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCINE METHYLTRANSFERASE; I PIPECOLIC ACID OXIDASE; KI 67 ANTIGEN; OXIDOREDUCTASE; PROGESTERONE RECEPTOR; SARCOSINE; SARCOSINE DEHYDROGENASE; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; SARCOSINE OXIDASE;

ADULT; AMINO ACID METABOLISM; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE DOSAGE; HER 2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; GLYCINE N-METHYLTRANSFERASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SARCOSINE; SARCOSINE DEHYDROGENASE; SARCOSINE OXIDASE;

EID: 84901824085     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-149     Document Type: Article

References (31)

1. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914. 10.1038/nature07762, 2724746, 19212411.
2. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013, 15:491-501. 3638352, 23633921.
3. Baum CE, Price DK, Figg WD. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Ther 2010, 9:341-342. 10.4161/cbt.9.5.11310, 2874119, 20150759.
4. Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, Kizek R, Adam V. Sarcosine as a potential prostate cancer biomarker-a review. Int J Mol Sci 2013, 14:13893-13908. 10.3390/ijms140713893, 3742224, 23880848.
5. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
6. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
7. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
8. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011, 26:1279-1286.
9. Choi J, Jung WH, Koo JS. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 2013, 80:41-52. 10.1159/000339513, 22832328.
10. Kim S, Kim do H, Jung WH, Koo JS. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer 2013, 20:339-348. 10.1530/ERC-12-0398, 23507704.
11. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992, 305:855-857. 10.1136/bmj.305.6858.855, 1883041, 1422397.
12. Sellers TA, Potter JD, Rich SS, Drinkard CR, Bostick RM, Kushi LH, Zheng W, Folsom AR. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994, 86:1860-1865. 10.1093/jnci/86.24.1860, 7990161.
13. Zhu X, Daffada AA, Chan CM, Dowsett M. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 1997, 72:574-580. 10.1002/(SICI)1097-0215(19970807)72:4<574::AID-IJC4>3.0.CO;2-N, 9259393.
14. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343:692-695. 10.1016/S0140-6736(94)91578-4, 7907678.
15. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408. 10.1056/NEJM199705153362001, 9145676.
16. Diamandis EP, Yu H, Sutherland DJ. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994, 32:301-310. 10.1007/BF00666007, 7532468.
17. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995, 55:2104-2110.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 1991, 19:403-410.
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
21. Won KY, Kim GY, Kim YW, Song JY, Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010, 41:107-112. 10.1016/j.humpath.2009.07.006, 19762066.
22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
23. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011, 185:706-711. 10.1016/j.juro.2010.09.077, 21168877.
24. Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno P. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 2012, 72:1611-1621. 10.1002/pros.22514, 22430630.
25. Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, Trabucco S, Di Clemente D, Selvaggi FP, Battaglia M, Ditonno P. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J Urol 2013, 190:2271-2277. 10.1016/j.juro.2013.05.004, 23665271.
26. Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K, Dannenberg AJ. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) 2012, 5:1358-1367. 10.1158/1940-6207.CAPR-12-0160, 3518611, 22961778.
27. Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep 2011, 38:4237-4243. 10.1007/s11033-010-0442-2, 3402037, 21755295.
28. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
29. Lucarelli G, Ditonno P, Bettocchi C, Spilotros M, Rutigliano M, Vavallo A, Galleggiante V, Fanelli M, Larocca AM, Germinario CA, Maiorano E, Selvaggi FP, Battaglia M. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. Future Oncol 2013, 9:899-907. 10.2217/fon.13.50, 23718310.
30. Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011, 24:1272-1280. 10.1038/modpathol.2011.76, 21572396.
31. Huang YC, Chen M, Shyr YM, Su CH, Chen CK, Li AF, Ho DM, Chen YM. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. J Gastroenterol Hepatol 2008, 23:1384-1389. 10.1111/j.1440-1746.2008.05488.x, 18624901.